Liposome-entrapped D. pteronyssinus vaccination in mild asthma patients: Effect of 1-year double-blind, placebo-controlled trial on inflammation, bronchial hyperresponsiveness and immediate and late bronchial responses to the allergen

Clinical and Experimental Allergy

Volumn 32, Issue 11, 2002, Pages 1574-1582

  Alvarez, M J ^a   Echechipia S ^a   Garcia B ^a   Tabar, A I ^a   Martin S ^b   Rico, P ^b   Olaguibel, J M ^a,c  

^a Universidad Pública de Navarra   (Spain)

^b ALK ABELLÓ   (Denmark)

^c Centro de Salud Conde Oliveto   (Spain)

Author keywords

Allergen bronchial challenge; Allergen vaccination; Dermatophagoides pteronyssinus; Dose response slope; Eosinophilic inflammation; Liposomes; Maximal response plateau; Mild asthma; Randomized double blind placebo controlled trial

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; HOUSE DUST ALLERGEN; IMMUNOLIPOSOME; INTERCELLULAR ADHESION MOLECULE 1; METHACHOLINE; METHACHOLINE CHLORIDE; PLACEBO; VACCINE; BRONCHOCONSTRICTING AGENT; DERMATOPHAGOIDES PTERONYSSINUS ANTIGEN P 1; DIAGNOSTIC AGENT; EOSINOPHIL GRANULE PROTEIN; LIPOSOME; PLASMA PROTEIN; RIBONUCLEASE;

ADULT; ALLERGIC ASTHMA; ARTICLE; BLOOD SAMPLING; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HOUSE DUST ALLERGY; HUMAN; HUMAN CELL; IMMEDIATE TYPE HYPERSENSITIVITY; INFLAMMATION; INHALATION TEST; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SPUTUM EXAMINATION; TREATMENT OUTCOME; VACCINATION; ASTHMA; BLOOD; BRONCHUS; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; IMMUNOTHERAPY; LEUKOCYTE COUNT; METHODOLOGY; NONPARAMETRIC TEST; SPUTUM;

ADULT; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BLOOD PROTEINS; BRONCHI; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; DERMATOPHAGOIDES PTERONYSSINUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; FEMALE; HUMANS; IMMUNOLOGIC TESTS; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTE COUNT; LIPOSOMES; MALE; METHACHOLINE CHLORIDE; RIBONUCLEASES; SPUTUM; STATISTICS, NONPARAMETRIC;

EID: 0036436280     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2002.01514.x     Document Type: Article

References (36)

1. Squillace SP, Sporik RB, Rakes G et al. Sensitization to dust mites as a dominant risk factor for asthma among adolescents living in central Virginia. Multiple regression analysis of a population-based study. Am J Respir Crit Care Med 1997; 156:1760-4.
2. Bousquet J, Michel FB. International consensus report on diagnosis and management of asthma. Allergy 1992; 47:129-32.
3. Bousquet J, Lockey R, Malling H. WHO Position Paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998; 53:3-42.
4. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151:969-74.
5. Van Bever H, Stevens W. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus) Eur Respir J 1992; 5:318-22.
6. Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52:853-9.
7. Pichler CE, Marquardsen A, Sparholt S et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997; 52:274-83.
8. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: Clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91:709-22.
9. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102:157-64.
10. Akdis CA, Blaser K. Immunologic mechanisms of allergen-specific immunotherapy. (Principles of specific immunotherapy of IgE-induced allergic reactions.) Adv Exp Med Biol 2001; 495:247-59.
11. Kohno Y, Minoguchi K, Oda N et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998; 102:927-34.
12. Boner AL, Peroni D, Sette L, Valletta EA, Piacentini G. Effects of allergen exposure-avoidance on inflammation in asthmatic children. Allergy 1993; 48:119-23.
13. Durham SR, Graneek BJ, Hawkins R, Taylor AJ. The temporal relationship between increases in airway responsiveness to histamine and late asthmatic responses induced by occupational agents. J Allergy Clin Immunol 1987; 79:398-406.
14. Sterk PJ, Bel EH. Bronchial hyperresponsiveness: The need for a distinction between hypersensitivity and excessive airway narrowing. Eur Respir J 1989; 2:267-74.
15. Woolcock AJ, Salome CM, Yan K. The shape of the dose-response curve to histamine in asthmatic and normal subjects. Am Rev Respir Dis 1984; 130:71-5.
16. Sterk PJ, Bel EH. The shape of the dose-response curve to inhaled bronchoconstrictor agents in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143:1433-7.
17. Audera C, Ramirez J, Soler E, Carreira J. Liposomes as carriers for allergy immunotherapy. Clin Exp Allergy 1991; 21:139-44.
18. Sehra S, Chugh L, Gangal SV. Polarized TH1 responses by liposome-entrapped allergen and its potential in immunotherapy of allergic disorders. Clin Exp Allergy 1998; 28:1530-7.
19. Anderson P. Delivery systems for immunomodulatory proteins and peptides. Biodrugs 1997; 7:51-65.
20. Basomba A, Tabar A, Hernández F et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: A randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 2002; 109:943-8.
21. Guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute. National Asthma Education Program. Expert Panel Report. J Allergy Clin Immunol 1991; 88:425-534.
22. Lombardero M, Gonzalez R, Duffort O et al. Evaluation of the total activity and allergenic composition of allergenic extracts. Allergol Immunopathol 1986; 14:189-98.
23. Ventas P, Lombardero M, Duffort O, Carreira J. Cuantificación de los alergenos Der p 1 y Der f 1 de los ácaros y Fel d 1 de gato mediante un ELISA en fase sólida. Rev Esp Alergol Inmunol Clin 1990; 5:71-5.
24. Bangham A, Hill M, Miller N. Preparation and use of liposomes as models of biological membranes. In: Korn, ED, ed. Methods in Membrane Biology. New York: Plenum Press, 1974:1-68.
25. Tovey E, Chapman M, Wells C, Platts-Mills T. The distribution of dust mite allergen in the houses of patients with asthma. Am Rev Respir Dis 1981; 124:630-5.
26. Dreborg S, Einarsson R, Lau S, Munir A, Wahn U. Dust sampling for determination of allergen content. Allergy 1995; 50:188-9.
27. Crapo R, Morris A, Gardner R. Reference spirometric values using techniques and equipment that meets the ATS recommendations. Am Rev Respir Dis 1981; 123:659-64.
28. Abramson MJ, Saunders NA, Hensley MJ. Analysis of bronchial reactivity in epidemiological studies. Thorax 1990; 45:924-9.
29. Alvarez MJ, Olaguibel JM, Garcia BE, Tabar AI, Urbiola E. Comparison of allergen-induced changes in bronchial hyperresponsiveness and airway inflammation between mildly allergic asthma patients and allergic rhinitis patients. Allergy 2000; 55:531-9.
30. Moore BJ, King GG, D'Yachkova Y, Ahmad HR, Pare PD. Mechanism of methacholine dose-response plateaus in normal subjects. Am J Respir Crit Care Med 1998; 158:666-9.
31. Valletta EA, Comis A, Del Col G, Spezia E, Boner AL. Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposure. Allergy 1995; 50:366-9.
32. Gabrielsson S, Soderlund A, Paulie S, Van Der Pouw Kraan TC, Troye-Blomberg M, Rak S. Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy 2001; 56:293-300.
33. Rak S. Effects of immunotherapy on the inflammation in pollen asthma. Allergy 1993; 48:125-8.
34. El-Sawy IH, Badr-El-Din OM, El-Azzouni OE, Motawae HA. Soluble intercellular adhesion molecule-1 in sera of children with bronchial asthma exacerbation. Int Arch Allergy Immunol 1999; 119:126-32.
35. Lee YC, Cheon KT, Rhee YK. Changes of soluble ICAM-1 levels in serum and bronchoalveolar lavage fluid from patients with atopic bronchial asthma after allergen challenge. J Asthma 1997; 34:405-12.
36. Finkelman FD, Urban JF Jr. The other side of the coin: The protective role of the TH2 cytokines. J Allergy Clin Immunol 2001; 107:772-80.